|
- Anne Wojcicki to buy back 23andMe and its data for $305 million - CNBC
Anne Wojcicki's nonprofit will acquire substantially all of 23andMe's assets for $305 million, the company announced Friday 23andMe filed for Chapter 11 bankruptcy protection in March
- 23andMe Cofounder Anne Wojcicki Wins Bid, Takes Back Company | Entrepreneur
TTAM, a nonprofit led by 23andMe founder Anne Wojcicki, is the new buyer of 23andMe's assets with a bid of $305 million
- Nonprofit run by former CEO Anne Wojcicki wins bid to acquire 23andMe
A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for $305 million Wojcicki’s return is likely to spark lawsuits The
- Anne Wojcicki’s nonprofit wins bid to acquire genetic testing company . . .
The California-based nonprofit founded by the former 23andMe CEO is set to close the $305 million deal in coming weeks
- Anne Wojcicki wins bid to buy back 23andMe for $305M
Dive Brief: Anne Wojcicki, co-founder and former CEO of 23andMe, will buy back “substantially all” of the genetic testing firm’s assets, 23andMe announced Friday A bankruptcy court must still approve the sale The nonprofit TTAM Research Institute — an acronym for 23andMe — outbid Regeneron with a purchase price of $305 million
- From $6B Valuation to Bankruptcy to Rescue: Wojcicki Reclaims 23andMe . . .
Anne Wojcicki, co-founder and former CEO of 23andMe, will regain control of the embattled genetic testing company through a $305 million acquisition by her nonprofit TTAM Research Institute, the
- 23andMe founder saves company with last-minute $305 million bid
In a dramatic last-minute rescue, 23andMe co-founder Anne Wojcicki has outbid a pharmaceutical company to save her genetic testing startup from bankruptcy, potentially protecting the DNA
- Anne Wojcicki to buy back 23andMe and its data for $305 million - MSN
Anne Wojcicki, the co-founder and former CEO of 23andMe, has regained control over the embattled genetic testing company after her new nonprofit, TTAM Research Institute, outbid Regeneron
|
|
|